Moderna shares nearly tripled on Wednesday after a late-stage melanoma vaccine trial validated the company's mRNA platform beyond Covid, triggering a short squeeze that left bearish investors nursing paper losses near $5 billion. The 177% single-session surge pushed the stock to a multi-year high and extended a year-to-date advance of 465%, a repricing that turned a pandemic-era darling back into a biotech bellwether in the span of one trading day.
The trial that changed the valuation
The catalyst was a Phase 3 study of mRNA-4157, a personalized cancer vaccine developed with Merck, in more than 1,100 high-risk melanoma patients. The combination of the vaccine and Merck's Keytruda reduced the risk of recurrence and slowed disease spread compared with Keytruda alone, the first time a late-stage trial has improved on the established immunotherapy in this setting. For a company whose shares had traded as low as $22.28 over the past 52 weeks, the result was treated as proof of concept for an entire pipeline targeting lung, kidney and bladder cancers.
The short position that lit the fuse
As much as 12% of Moderna's float had been sold short in recent weeks, a concentration that turned Wednesday's rally into a stampede. When the data hit, bearish investors were forced to buy back shares to limit losses, their covering volume feeding on itself in a classic short squeeze. By the close, paper losses on those positions approached $5 billion, a figure that underscores how completely the market had written off the mRNA platform after the Covid revenue cliff.
The price target that hasn't moved
Wall Street's consensus price target sits at $66.25, less than half of Wednesday's close and well below the 52-week high of $176.66. The gap between analyst models and the tape reflects a deeper uncertainty: the melanoma data is real, but the commercial path for personalized vaccines, manufacturing complexity, pricing, reimbursement, remains unproven at scale. The market just priced the platform as if those hurdles have already been cleared.
What the pipeline must now deliver
Moderna's next readouts in non-small cell lung cancer and renal cell carcinoma will determine whether Wednesday's move was a re-rating or a squeeze-induced overshoot. The company has not disclosed timelines for those trials, and the personalized manufacturing process has yet to be tested commercially. Until then, the stock trades on option value, not cash flow, a distinction that tends to blur in a short squeeze but reasserts itself once the covering is done.